On 6 November 2026, CMOC (03993.HK) unveiled an A-share buyback of RMB 1-2 billion at up to RMB 22.78 per share over three months, or 0.21%-0.41% of capital.
On 6 November 2026, JIUMAOJIU granted 46,570,000 share options to 128 eligible persons at HKD0.935, about 3.48% of its issued shares excluding treasury shares.
On 6 November 2026, TIME INTERCON said its board approved buying back up to HKD500 million of its shares over 24 months, funded from internal resources.
On 6 November 2026, HUANENG POWER said the Huaneng Coal Power REIT listed in Shanghai under code 508081 after raising RMB3.198 billion net at RMB3.198 per unit.
On 6 November 2026, CSPC PHARMA said the Phase I/II trial of SYS6055, an in vivo CAR-T therapy for B-cell lymphoma, started at its first site in China.
On 6 November 2026, MICROTECH MED-B said the Exchange approved listing of 250,087,968 H shares under full circulation on 5 November, pending conditions.
On 6 November 2026, DIAGENS-B signed a three-year strategic pact with Yongjiang Laboratory to advance medical imaging AI training and use in Guangxi, China.
On 6 November 2026, CSPC PHARMA said the Phase II trial of SYH9061, a nintedanib dry powder inhaler for idiopathic pulmonary fibrosis, started in China.
On 6 November 2026, CHALCO said its board approved an RMB6.55557 billion EPC contract with CHALIECO for the Guinea alumina project, a connected transaction.
On 6 November 2026, GF SEC said its two 2025 sixth tranche bond tranches totalling RMB4.47 billion will pay interest on 10 November at 1.84% and 2.03%.
On 6 November 2026, SHANDONG XINHUA said it obtained China's drug registration certificate for ketorolac tromethamine injection, a Class 3 chemical drug.
On 6 November 2026, CHINA SUNTIEN said NAFMII accepted the registration of its RMB3 billion medium-term notes, valid for two years from 3 November 2026.
On 6 November 2026, VIRTUAL MIND said chairman Mei Weiyi bought 552,000 shares of the Company on market, raising his holding to 25,342,000 shares, or 2.31%.
On 6 November 2026, JIUYUAN GENE said the IND for JY54-2 Injection, a long-acting amylin analogue, was accepted for type 2 diabetes and weight management.
On November 6, the HSI fell 1.27% and the HSTECH 1.83%. MICOT PHARMA-B led Stock Connect gainers at 15.19%, while southbound funds bought HK$2.415 billion net.
On November 6, the HSI fell 1.27% and the HSTECH 1.83%. ROBOSENSE rose 6.46% on a new automated LiDAR production line, while 16 of 20 AI concept stocks fell.
